TuisMOLN • NASDAQ
add
Molecular Partners AG
Vorige sluiting
$6,78
Dagwisseling
$6,23 - $7,60
Jaarwisseling
$3,32 - $12,70
Markkapitalisasie
234,39 m USD
Gemiddelde volume
20,79 k
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
(CHF) | Jun. 2024info | J/J-verandering |
---|---|---|
Inkomste | 1,55 m | 273,73% |
Bedryfskoste | 4,44 m | -4,84% |
Netto inkomste | -15,08 m | 5,66% |
Netto winsgrens | -972,40 | 74,76% |
Wins per aandeel | — | — |
EBITDA | -15,37 m | -0,62% |
Effektiewe belastingkoers | — | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
(CHF) | Jun. 2024info | J/J-verandering |
---|---|---|
Kontant en korttermynbeleggings | 159,13 m | -27,07% |
Totale bates | 170,62 m | -25,98% |
Totale aanspreeklikheid | 15,05 m | -38,62% |
Totale ekwiteit | 155,57 m | — |
Uitstaande aandele | 33,18 m | — |
Prys om te bespreek | 1,45 | — |
Opbrengs op bates | -22,42% | — |
Opbrengs op kapitaal | -24,17% | — |
Kontantvloei
Netto kontantverandering
(CHF) | Jun. 2024info | J/J-verandering |
---|---|---|
Netto inkomste | -15,08 m | 5,66% |
Kontant van bedrywe | -15,72 m | -18,38% |
Kontant van beleggings | 13,15 m | 225,87% |
Kontant van finansiering | -267,00 k | 2,55% |
Netto kontantverandering | -2,66 m | 75,12% |
Beskikbare kontantvloei | -9,80 m | -15,75% |
Meer oor
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development. Wikipedia
Gestig
2004
Webwerf
Werknemers
162